avenues that could potentially improve the drug development process, according to several participants. Patient stratification, target identification based on human data, systematic evaluations of failed clinical trials, and improved guidance on regulatory issues were just a few potential solutions that participants considered. Finally, several speakers and participants advocated for open data sharing among researchers and a centralized database for all preclinical trials to increase collaborative efforts and decrease replication in the field.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement